Use of mycophenolate mofetil in patients with severe localized scleroderma resistant or intolerant to methotrexate
Files
Publication date
2016
Authors
Mertens, Jorre S.
Marsman, Diane
van de Kerkhof, Peter C M
Hoppenreijs, Esther P A H
Knaapen, Hanneke K A
Radstake, Timothy R D J
de Jong, Elke M G J
Seyger, Marieke M B
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
To assess the efficacy and safety of mycophenolate mofetil (MMF) in patients with localized scleroderma (LoS) resistant or intolerant to previous treatment with methotrexate (MTX). A case series of patients with LoS treated with MMF. Outcome was assessed through clinical examination. Adverse events were documented. Seven patients with LoS were treated with MMF. Median age at MMF initiation was 15 years (range 7–74 years). Three patients received MMF due to MTX ineffectiveness and 4 due to MTX intolerance. Disease remission was achieved in 4 patients and maintained in one patient. One patient showed a favourable response, but had to discontinue treatment due to elevated liver enzymes. The remaining patient experienced disease progression. MMF was shown to improve the clinical condition of patients with refractory LoS and may be a relatively safe alternative in patients who are intolerant to MTX.
Keywords
Localized scleroderma, Methotrexate, Morphea, Mycophenolate mofetil, Dermatology, Journal Article
Citation
Mertens, J S, Marsman, D, van de Kerkhof, P C M, Hoppenreijs, E P A H, Knaapen, H K A, Radstake, T R D, de Jong, E M G J & Seyger, M M B 2016, 'Use of mycophenolate mofetil in patients with severe localized scleroderma resistant or intolerant to methotrexate', Acta Dermato-Venereologica, vol. 96, no. 4, pp. 510-513. https://doi.org/10.2340/00015555-2297